Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Inhibidores de proteasas de serina con características similares a las de los medicamentos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20180807001
Publicado:
15/08/2018
Caducidad:
16/08/2019
Resumen:
Una universidad alemana ha descubierto inhibidores de primera clase que influyen en las proteasas de serina asociadas con la degeneración macular e isquemia-reperfusión. Los investigadores han demostrado que los Ahp-ciclodepsipéptidos representan un andamio adecuado para generar inhibidores de proteasas de serina. Hasta ahora no existen inhibidores con características similares a las de los medicamentos. La universidad busca socios en los sectores de enfermedades oculares y trastornos cardiovasculares con el fin de establecer acuerdos de licencia o cooperación en materia de investigación.

Details

Tittle:
Inhibitors of serine proteases with drug-like characteristics
Summary:
A German university found first-in-class inhibitors influencing the serine proteases associated with macular degeneration and reperfusion-ischemia. So far no inhibitors with drug-like characteristics have been available. The German university offers a license and/or research cooperation agreement.
Description:
High Temperature Requirement A (HTRA) proteins are serine proteases of the S1 family (trypsin/chymotrypsin-like). HTRA1 is supposed to play a role in macular degeneration, and HTRA2 has been associated with cell death in reperfusion-ischemia. Therefore, HTRA proteins might represent novel therapeutic targets. However, currently no inhibitors with drug-like characteristics and thus promising potential for pharmaceutical development are available.

Researchers of a German university have now demonstrated that Ahp-cyclodepsipeptides represent a suitable scaffold for generating target-tailored inhibitors of serine proteases. They have developed a practical mixed solid- and solution-phase synthesis that allows the customized synthesis of Ahp-cyclodepsipeptides and thus tailored inhibitor synthesis. The applicability of this approach was shown by the generation of the most potent human HTRA1 as well as HTRA2 protease inhibitors to date (see figure). Inhibitory potency of the synthesized substances was proven in binding studies and cell-based assays.

The university offers a license cooperation agreement to pharmaceutical companies who would integrate the findings in their product development. The invention is in an early stage and that is why a research cooperation agreement is also offered to further advance the invention. Partners would be active in the field of eye diseases or cardiovascular disorders.
Advantages and Innovations:
The enzymes HTRA1 and HTRA2 have not yet been pharmacologically addressed. Currently no inhibitors with drug-like characteristics and thus promising potential for pharmaceutical development are available. Ahp-cyclodepsipeptides constitute a novel class of HTRA inhibitors and are thus qualified to be further developed as "first-in-class" drugs for that target.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A patent at the World Intellectual Property Organization has been applied for.

Partner sought

Type and Role of Partner Sought:
The German university offers a license cooperation agreement to pharmaceutical companies working in the indication field of eye diseases or cardiovascular disorders and who would like to integrate the findings in their product development. The inhibitors are at an early stage of development. Thus a research cooperation agreement is also conceivable in order to adapt for markt readiness. In the initial phase (preclinical), the university could contribute to the optimisation of the substances for further development into a drug.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002008 Microbiología
06001015 Productos farmacéuticos / medicamentos
06002003 Tecnología de enzimas